dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
Published 7 years ago • 339 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:14
dr. zelenetz on nivolumab plus ibrutinib in patients with cll
-
1:58
dr. zelenetz on current treatment options for mcl
-
2:05
dr. zelenetz on potential of acalabrutinib and bgb-3111 in cll
-
2:14
dr. jeffrey jones on idelalisib and ibrutinib in patients with cll
-
1:17
dr. mato on managing side effects with ibrutinib/idelalisib in cll
-
1:24
dr. andrew zelenetz discusses treatment options for dlbcl
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:00
dr. shpall on therapeutic agents for the treatment of cll
-
1:16
dr. kipps on ibrutinib and idelalisib for cll
-
2:30
dr. andrew zelenetz on the treatment of hematologic malignancies
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
1:24
dr. jennifer brown on ibrutinib, idelalisib, and other agents for cll
-
1:00
dr. jain on the combination of idelalisib and rituximab for older patients with cll
-
11:28
adverse events of ibrutinib in chronic lymphocytic leukemia
-
1:32
dr. zelenetz on zanubrutinib research in mcl
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
1:29
dr. byrd on ibrutinib's impact on treatment landscape in cll
-
2:04
dr. chavez on ongoing efficacy and challenges with ibrutinib in cll